Results of AGM

SkinBioTherapeutics plc

("SkinBioTherapeutics" or the "Company")

 

Results of AGM

 

30 December 2022 -  SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held yesterday 29 December 2022, all resolutions were duly passed.

 

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 

Resolution		For & Discretionary		Against		Withheld
		Number of votes	%	Number of votes	%	Number of votes	%
01	Ordinary resolution to re-elect Stuart Ashman as a director	2,383,037	92.09%	186,041	7.19%	18,760	0.72%
02	Ordinary resolution to re-elect Martin Hunt as a director	2,421,721	93.58%	147,357	5.69%	18,760	0.72%
03	Ordinary resolution to re-elect Dr Cathy Prescott as a director	2,433,015	94.02%	136,063	5.26%	18,760	0.72%
04	Ordinary resolution to re-elect D anielle Bekker as a director	2,421,721	93.58%	147,357	5.69%	18,760	0.72%
05	Ordinary resolution to re-elect M anprit Singh Randhawa as a director	2,421,721	93.58%	147,357	5.69%	18,760	0.72%
06	Ordinary resolution to authorise the directors to allot shares	2,385,561	92.18%	184,828	7.14%	17,449	0.67%
07	Special resolution to authorise the directors to disapply pre-emption rights	2,375,561	91.80%	194,828	7.53%	17,449	0.67%
08	Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment	2,383,037	92.09%	186,041	7.19%	18,760	0.72%

 

-Ends-

 For more information, please contact:

SkinBioTherapeutics plc Stuart J . Ashman, CEO Manprit Randhawa, CFO	Tel: +44 (0) 191 495 7325
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: +44 (0) 20 7397 8900
Instinctif Partners (financial press) Melanie Toyne-Sewell / Tim Field	Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics @instinctif.com

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com .